Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany

被引:29
作者
Rueschoff, Josef [1 ,2 ]
Lebeau, Annette [3 ,4 ]
Kreipe, Hans [5 ]
Sinn, Peter [6 ]
Gerharz, Claus Dieter [7 ]
Koch, Winfried [8 ]
Morris, Stefanie [9 ]
Ammann, Johannes [9 ]
Untch, Michael [10 ]
机构
[1] Inst Pathol Nordhessen, Kassel, Germany
[2] Targos Mol Pathol GmbH, Kassel, Germany
[3] Univ Klinikum Hamburg Eppendorf, Inst Pathol, Hamburg, Germany
[4] Gemeinschaftspraxis Pathol, Lubeck, Germany
[5] Hannover Med Sch, Inst Pathol, Hannover, Germany
[6] Inst Pathol, Sekt Gynakopathol, Heidelberg, Germany
[7] Evangel Bethesda Clin Ctr, Inst Pathol, Duisburg, Germany
[8] Biostat Data Serv Koch, Schwetzingen, Germany
[9] Roche Pharma AG, Grenzach Wyhlen, Germany
[10] Breast Canc Ctr, Clin Gynecol Gynecol Oncol & Obstet, Berlin, Germany
关键词
SURGICAL ADJUVANT BREAST; MONOCLONAL-ANTIBODY; AMERICAN SOCIETY; PLUS TRASTUZUMAB; HEART-FAILURE; SAFETY; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY; DOXORUBICIN; PERTUZUMAB;
D O I
10.1038/modpathol.2016.164
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Despite >10 years of routine human epidermal growth factor receptor 2 (HER2) testing in breast cancer, testing quality is still an issue. Guidelines recommend assessing HER2 positivity rates as a quality indicator; however, the extent to which patient- or tumor-related factors influence HER2 positivity is still unknown. The present study analyzed these influences to identify pathology centers with HER2 positivity rates unexplained by patient- or tumor-related factors. This observational, prospective study monitored routine HER2 testing at 57 institutes of pathology in Germany (January 2013-August 2014). Data collected included HER2 test result, patient- and tumor-related factors, sample source, and method of sample retrieval. Factors influencing HER2 positivity rates were identified by multiple logistic regression. Individual center effects were assessed in an extended multiple logistic regression model by their statistical significance after adjusting for the combined effect of patient- or tumor-related covariates and multiple testing. Analyses included 15 332 invasive breast cancer samples. Histologic grade showed the strongest influence on HER2 positivity, followed by hormone receptor status, histologic subtype, age, and nodal status (all P < 0.0001). The overall HER2 positivity rate across centers was 14.4% (range 7.1-27.3%). A statistically significant center effect on the HER2 positivity rate was identified for three centers (P < 0.05), with a trend toward a center effect for a further three (P < 0.2). This study, the first of its kind, highlights that assessing HER2 testing quality with HER2 positivity rates should include standardized assessment of patient- or tumor-related characteristics to identify centers with HER2 testing quality issues more effectively. As treatment options for HER2-positive breast cancer continue to evolve, identifying the right patients is key.
引用
收藏
页码:217 / 226
页数:10
相关论文
共 37 条
[1]  
Avril S, 2014, 37 SAN ANT BREAST CA
[2]   External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme [J].
Bartlett, John M. S. ;
Ibrahim, Merdol ;
Jasani, Bharat ;
Morgan, John M. ;
Ellis, Ian ;
Kay, Elaine ;
Magee, Hilary ;
Barnett, Sarah ;
Miller, Keith .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) :816-819
[3]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[4]   Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations [J].
Bianchi, S. ;
Caini, S. ;
Paglierani, M. ;
Saieva, C. ;
Vezzosi, V. ;
Baroni, G. ;
Simoni, A. ;
Palli, D. .
PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (02) :477-485
[5]   Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program [J].
Bilous, Michael ;
Morey, Adrienne L. ;
Armes, Jane E. ;
Bell, Richard ;
Button, Peter H. ;
Cummings, Margaret C. ;
Fox, Stephen B. ;
Francis, Glenn D. ;
Waite, Brigid ;
McCue, Glenda ;
Raymond, Wendy A. ;
Robbins, Peter D. ;
Farshid, Gelareh .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) :617-624
[6]   Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study [J].
Bowles, Erin J. Aiello ;
Wellman, Robert ;
Feigelson, Heather Spencer ;
Onitilo, Adedayo A. ;
Freedman, Andrew N. ;
Delate, Thomas ;
Allen, Larry A. ;
Nekhlyudov, Larissa ;
Goddard, Katrina A. B. ;
Davis, Robert L. ;
Habel, Laurel A. ;
Yood, Marianne Ulcickas ;
McCarty, Catherine ;
Magid, David J. ;
Wagner, Edward H. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17) :1293-1305
[7]   ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].
Cardoso, F. ;
Costa, A. ;
Norton, L. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Biganzoli, L. ;
Blackwell, K. L. ;
Cardoso, M. J. ;
Cufer, T. ;
El Saghir, N. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Giordano, S. H. ;
Gligorov, J. ;
Goldhirsch, A. ;
Harbeck, N. ;
Houssami, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Kyriakides, S. ;
Lin, U. N. ;
Mayer, M. ;
Merjaver, S. D. ;
Nordstrom, E. B. ;
Pagani, O. ;
Partridge, A. ;
Penault-Llorca, F. ;
Piccart, M. J. ;
Rugo, H. ;
Sledge, G. ;
Thomssen, C. ;
van't Veer, L. ;
Vorobiof, D. ;
Vrieling, C. ;
West, N. ;
Xu, B. ;
Winer, E. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1871-1888
[8]   Quality assessment of HER2 testing by monitoring of positivity rates [J].
Choritz, Harald ;
Buesche, Guntram ;
Kreipe, Hans .
VIRCHOWS ARCHIV, 2011, 459 (03) :283-289
[9]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[10]   HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [J].
Denkert, Carsten ;
Huober, Jens ;
Loibl, Sibylle ;
Prinzler, Judith ;
Kronenwett, Ralf ;
Darb-Esfahani, Silvia ;
Brase, Jan C. ;
Solbach, Christine ;
Mehta, Keyur ;
Fasching, Peter A. ;
Sinn, Bruno V. ;
Engels, Knut ;
Reinisch, Mattea ;
Hansmann, Martin-Leo ;
Tesch, Hans ;
von Minckwitz, Gunter ;
Untch, Michael .
BREAST CANCER RESEARCH, 2013, 15 (01)